Agilent Technologies, Inc. (A)
NYSE · Healthcare · Medical - Diagnostics & Research
Profile
Agilent Technologies, Inc.
- Exchange
- NYSE
- Ticker
- A
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- US
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
Key facts
Agilent Technologies, Inc.: key facts
- Agilent Technologies, Inc. (NYSE: A) is a Medical - Diagnostics & Research company in the Healthcare sector.
- In fiscal 2025, Agilent Technologies, Inc. reported revenue of $6.9B and net income of $1.3B.
- Revenue grew 2.4% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $7.4B and net income was $1.4B.
MonkScore
Agilent Technologies, Inc.'s MonkScore
MonkScore
MonkScore range: 70–80
as of October 2026
Sector rank: 146 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth50–60
- Profitability70–80
- Quality50–60
- Market Conviction90–100
- Safety30–40
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Agilent Technologies, Inc.'s annual figures and the last twelve months, in USD. Last report: 31 July 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $7.4B | $6.9B | $6.5B | $6.8B | $6.8B | $6.3B |
| Gross profit | $4.0B | $3.6B | $3.5B | $3.5B | $3.7B | $3.4B |
| Operating income | $1.6B | $1.5B | $1.5B | $1.4B | $1.6B | $1.3B |
| Net income | $1.4B | $1.3B | $1.3B | $1.2B | $1.3B | $1.2B |
| Operating cash flow | $1.6B | $1.6B | $1.8B | $1.8B | $1.3B | $1.5B |
| Capital expenditure | -$173.0M | -$407.0M | -$378.0M | -$298.0M | -$291.0M | -$189.0M |
| Free cash flow | $1.4B | $1.2B | $1.4B | $1.5B | $1.0B | $1.3B |
| Total debt | $3.9B | $3.4B | $3.6B | $2.7B | $2.8B | $2.7B |
| Cash | $1.8B | $1.8B | $1.3B | $1.6B | $1.1B | $1.5B |
Revenue growth a year
- 1-year
- 6.7%
- 3-year
- 0.5%
- 4-year
- 2.4%
Compound growth between fiscal years.
Peers
Similar companies
- Mettler-Toledo International Inc.NYSE:MTDMonkScore range: 90–100
- Illumina, Inc.NASDAQ:ILMNMonkScore range: 90–100
- CareDx, IncNASDAQ:CDNAMonkScore range: 90–100
- Medpace Holdings, Inc.NASDAQ:MEDPMonkScore range: 90–100
- IDEXX Laboratories, Inc.NASDAQ:IDXXMonkScore range: 90–100
Compare
Compare with
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.